---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-192031"
form_type: "8-K"
ticker: null
cik: "0001808865"
company_name: "iTeos Therapeutics, Inc."
filed_at: "2025-08-29T23:59:59+00:00"
generated_at: "2026-05-17T09:16:25.918373+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# iTeos Therapeutics acquired by Concentra Biosciences for $10.047/sh plus CVR

## Summary
- Tender offer closed with 72.17% of shares tendered; all conditions satisfied; merger effective Aug 29, 2025.
- Shareholders receive $10.047 cash per share plus one non-transferable CVR per share.
- CVR entitles holders to 80% of net proceeds from future disposition of specific product candidates (EOS-984, EOS-215, PTPN1/2 program) within 6-month disposition period.
- Board resigned; new directors/officers from Concentra (Kevin Tang CEO, Michael Hearne CFO, etc.).
- Company requests delisting from Nasdaq and intends to deregister with SEC.

## SEC filing metadata
- accession: 0001193125-25-192031
- form_type: 8-K
- cik: 0001808865
- company_name: iTeos Therapeutics, Inc.
- filed_at: 2025-08-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808865/000119312525192031/0001193125-25-192031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808865/000119312525192031/d938711d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-192031
- JSON: https://secwatch.observer/filing/0001193125-25-192031.json
- Plain text: https://secwatch.observer/filing/0001193125-25-192031.txt

## Key facts
- Governance Changes
  iTeos Therapeutics, Inc.: Bylaws amended and restated in their entirety.
  - Change: bylaw amendment
  source text: the Company's certificate of incorporation and bylaws were amended and restated in their entirety
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808865/000119312525192031/0001193125-25-192031-index.htm
- Governance Changes
  iTeos Therapeutics, Inc.: Certificate of incorporation amended and restated in its entirety.
  - Change: charter amendment
  source text: the Company's certificate of incorporation and bylaws were amended and restated in their entirety
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808865/000119312525192031/0001193125-25-192031-index.htm
- M&A Transactions
  iTeos Therapeutics, Inc. underwent a change of control involving Concentra Biosciences, LLC for $10.047 in cash per Share plus one non-transferable contractual contingent value right per Share (closed 2025-08-29).
  - Action: change of control
  - Counterparty: Concentra Biosciences, LLC
  - Consideration: $10.047 in cash per Share plus one non-transferable contractual contingent value right per Share
  - Closing: 2025-08-29
  source text: (the “Company”) in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on July 21, 2025, the Company entered into an Agreement and Plan of Merger, dated as of July 18, 2025 (the “Merger Agreement”) with Concentra Biosciences, LLC, a Delaware limited liability company (“Parent”), and Concentra Merger Sub VIII, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808865/000119312525192031/0001193125-25-192031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.